Antidrug Antibody Formation During Tumor Necrosis Factor Α Inhibitor Treatment of Severe Psoriatic Patients in the Real-Life Practice

Postepy Dermatologii I Alergologii - Poland
doi 10.5114/ada.2019.89507
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Termedia Sp. z.o.o.

Related search

Value of Antidrug Antibody Screening in Moderate-To-Severe Rheumatiod Arthritis Patients Who Failed Initial Tumor Necrosis Factor-Alpha Treatment

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2015English

Infliximab (Anti–Tumor Necrosis Factor Α Antibody)

Archives of Dermatology
2001English

Effect of the Biological Drug Etanercept on Tumor Necrosis Factor-Α Levels in Psoriatic Patients

Iraqi Journal of Science
GeneticsMolecular BiologyGeologyBiochemistryComputer ScienceBiotechnologyChemistry
2018English

Tumor Necrosis Factor Α Antagonists in the Treatment of the Patients With Rheumatoid Arthritis

Reumatologia
RheumatologyAllergyImmunology
2012English

Recognition of Human Tumor Necrosis Factor Α (TNF-α) by Therapeutic Antibody Fragment

Journal of Biological Chemistry
BiochemistryCell BiologyMolecular Biology
2012English

Tumor Necrosis Factor-Alpha Inhibitor Treatment for Sarcoidosis

Therapeutics and Clinical Risk Management
2008English

Vasculoprotective Effects of Anti-Tumor Necrosis Factor-Α Treatment in Aging

American Journal of Pathology
Forensic MedicinePathology
2007English

Predictors of Treatment Initiation With Tumor Necrosis Factor-Α Inhibitors in Patients With Rheumatoid Arthritis

Journal of Managed Care Pharmacy
2014English

Erratum To: Anti-Tumor Necrosis Factor-Α Therapy and Changes of Flow-Mediated Vasodilatation in Psoriatic and Rheumatoid Arthritis Patients

Internal and Emergency Medicine
Internal MedicineEmergency Medicine
2010English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy